Psoriasis, atopic dermatitis (AtD), and Alzheimer’s disease (AD) are chronic inflammatory disorders traditionally examined within isolated organ systems, but are increasingly recognized as manifestations of a shared immunometabolic architecture with direct relevance to cancer biology. Synthesizing multi-omics with transcriptomic and clinical evidence, this review delineated the conserved cytokine-driven networks linking cutaneous, neural, and oncologic inflammation. Core inflammatory loops centered on interleukin (IL)-1β, tumor necrosis factor-α (TNF-α), IL-6, IL-17A/F, and IL-23 were found to converge on Janus kinase (JAK)–signal transducer and activator of transcription (STAT), nuclear factor κB (NF-κB), and mitogen-activated protein kinase (MAPK) signaling across keratinocytes-, microglia-, and tumor-associated immune cells. Transcription factors (peroxisome proliferator activated receptor γ (PPARG), zinc finger protein, FOG family member 2 (ZFPM2), zinc finger protein 415 (ZNF415), H2.0 like homeobox (HLX), and anomalous homeobox (ANHX)) and long non-coding RNAs (metastasis associated lung adenocarcinoma transcript 1 ( MALAT1 ), nuclear enriched abundant transcript 1 ( NEAT1 ), psoriasis susceptibility-related induced by stress ( PRINS ), and β-site APP cleaving enzyme 1 antisense transcript ( BACE1-AS )) were found to form feed-forward regulatory circuits that sustained immune activation across tissues. Comparative immunogenomic analyses revealed overlapping inflammatory states among lesional skin, the Alzheimer’s brain, and tumor microenvironments, supporting a unified inflammatory continuum. Biologic agents and JAK inhibitors, originally developed for dermatologic diseases, were observed to provide mechanistic and therapeutic entry points for modulating neuroinflammation and tumor-promoting immune niches. These findings demonstrate that integrative systems biology and artificial intelligence (AI)-driven multimodal modeling frameworks enable immune-state stratification beyond organ boundaries, offering a precision-guided paradigm for cross-disease immunomodulation in neurodegeneration and cancer.
Iqbal et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: